** Morgan Stanley initiates coverage of drug development software provider Certara CERT.O with an "equal weight" rating
** "A key focus for the company is biosimulation, where Certara's platforms are designed to optimize drug design and testing" - Brokerage
** Morgan Stanley says CERT has a market-leading platform and generates strong recurring revenues with significant cross-selling opportunities
** Brokerage PT remains unchanged at $16, a ~39.3% upside on the stock's last close
** Five of 11 brokerages rate the stock "buy" or higher, six "hold"; their median PT is $16 - LSEG data
** As of last close, stock up ~7.9% YTD
(Reporting by Prakhar Srivastava in Bengaluru)
((Prakhar.srivastava2@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。